BG107831A - Комбинация от лекарства, по-специално хлорпромазин и пентамидин, за лечение на неопластични заболявания - Google Patents

Комбинация от лекарства, по-специално хлорпромазин и пентамидин, за лечение на неопластични заболявания Download PDF

Info

Publication number
BG107831A
BG107831A BG107831A BG10783103A BG107831A BG 107831 A BG107831 A BG 107831A BG 107831 A BG107831 A BG 107831A BG 10783103 A BG10783103 A BG 10783103A BG 107831 A BG107831 A BG 107831A
Authority
BG
Bulgaria
Prior art keywords
cancer
pentamidine
chlorpromazine
administered
neoplasm
Prior art date
Application number
BG107831A
Other languages
Bulgarian (bg)
English (en)
Inventor
Alexis Borisy
Curtis Keith
Michael A. Foley
Brent R. Stockwell
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of BG107831A publication Critical patent/BG107831A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BG107831A 2000-11-06 2003-05-20 Комбинация от лекарства, по-специално хлорпромазин и пентамидин, за лечение на неопластични заболявания BG107831A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/706,929 US6569853B1 (en) 2000-11-06 2000-11-06 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
PCT/US2001/047959 WO2002058684A2 (en) 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Publications (1)

Publication Number Publication Date
BG107831A true BG107831A (bg) 2004-02-27

Family

ID=24839666

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107831A BG107831A (bg) 2000-11-06 2003-05-20 Комбинация от лекарства, по-специално хлорпромазин и пентамидин, за лечение на неопластични заболявания

Country Status (29)

Country Link
US (4) US6569853B1 (zh)
EP (1) EP1339399B1 (zh)
JP (1) JP2004517915A (zh)
KR (1) KR100720205B1 (zh)
CN (1) CN1484525A (zh)
AR (1) AR035500A1 (zh)
AT (1) ATE318590T1 (zh)
AU (1) AU2002246636B8 (zh)
BG (1) BG107831A (zh)
BR (1) BR0115166A (zh)
CA (1) CA2436799C (zh)
CY (1) CY1105501T1 (zh)
DE (1) DE60117615T2 (zh)
DK (1) DK1339399T3 (zh)
EE (1) EE200300212A (zh)
ES (1) ES2258566T3 (zh)
HR (1) HRP20030460A2 (zh)
HU (1) HUP0400529A3 (zh)
IL (1) IL155795A0 (zh)
IS (1) IS2457B (zh)
MX (1) MXPA03003960A (zh)
NO (1) NO20032036L (zh)
NZ (1) NZ525773A (zh)
PL (1) PL362690A1 (zh)
PT (1) PT1339399E (zh)
RU (1) RU2286769C2 (zh)
SK (1) SK5452003A3 (zh)
TW (1) TWI259077B (zh)
WO (1) WO2002058684A2 (zh)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1231910B1 (en) * 1999-11-16 2009-05-20 Oncozyme Pharma Inc. Pentamidine for treating cancer
DE10015818A1 (de) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US6992082B2 (en) * 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
AU2002312170B8 (en) * 2001-05-31 2008-07-31 The Cleveland Clinic Foundation PTPase inhibitors and method of using same
FR2825279B1 (fr) * 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
CA2459793A1 (en) 2001-09-07 2003-08-28 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
WO2003092616A2 (en) * 2002-05-01 2003-11-13 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
BR0312597A (pt) * 2002-07-11 2005-05-10 Combinatorx Inc Combinações de drogas para o tratamento de neoplasmas
WO2004088272A2 (en) * 2003-03-26 2004-10-14 Synergy Biosystems Ltd. Methods to identify biologically active agents and synergistic combinations
EP2377528B1 (en) * 2003-06-12 2014-02-19 The Board of Regents of the University of Colorado Fatty acid metabolism inhibitors for use in the treatment of cancer
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
JP2007505914A (ja) * 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
ATE532517T1 (de) * 2003-11-13 2011-11-15 Noa Sic Aps Thioridazin und seine derivate zur umkehr von antimikrobieller arzneimittelresistenz
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
EP2574341B1 (en) 2004-03-29 2017-03-29 University Of South Florida Effective treatment of tumors and cancer with triciribine phosphate
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
MXPA06012566A (es) 2004-04-30 2007-05-09 Bkg Pharma Aps Tratamiento de enfermedades infecciosas.
WO2005117847A2 (en) * 2004-06-02 2005-12-15 Combinatorx, Incorporated Methods and compounds for the treatment of neoplasms
WO2006078774A2 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
EP1877060A2 (en) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Therapeutic bifunctional compounds
JP2008543734A (ja) * 2005-05-02 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 脂肪酸代謝および解糖の阻害を提供する化合物の組み合わせ、または二官能性化合物を用いるヒトの炎症性および増殖性疾患を処置するためのシステムおよび方法
EP1896007B1 (en) 2005-05-04 2014-03-19 Medigene AG Method of administering a cationic liposomal preparation comprising paclitexel
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
AU2006256369B2 (en) * 2005-06-07 2012-08-02 Bar-Ilan University Novel salts of conjugated psychotropic drugs and processes of preparing same
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
TW200803835A (en) * 2006-01-11 2008-01-16 Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
CA2659521A1 (en) * 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
WO2008080398A1 (en) * 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
DK2124857T3 (en) * 2007-01-09 2017-07-03 Fovea Pharmaceuticals DEVICE FOR INTRAOCULAR INJECTION
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
US20110009351A1 (en) * 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
CN101138558B (zh) * 2007-09-13 2010-08-25 汕头大学医学院 喷他脒及死亡结构域受体配体联合应用
EP2194981B1 (en) * 2007-10-05 2011-11-23 Université de Mons-Hainaut Bisbenzimidazoles as antimalarial agents
EP2252578B1 (en) * 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
WO2010009332A1 (en) * 2008-07-18 2010-01-21 Immune Control, Inc. Binding and inhibiting 5-ht4 receptor
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
WO2010125462A2 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
CA2760779A1 (en) 2009-05-20 2010-11-25 Hopitaux Universitaires De Geneve Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
WO2011035225A1 (en) * 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
MX2012006566A (es) * 2009-12-09 2012-11-29 Univ Ramot Metodo para mejorar las funciones cognoscitivas.
US20130165417A1 (en) * 2010-04-23 2013-06-27 University Of Florida Research Foundation Methods and compositions for treating ace2-related disorders
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
RS55557B1 (sr) * 2011-07-25 2017-05-31 Dritte Patentportfolio Beteili Amidoksimski estri karboksilnih kiselina pentamidina kao prolekovi i njihova primena kao lekova
CA2843338C (en) 2011-08-02 2020-08-25 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Selective inhibition of malt1 protease by phenothiazine derivatives
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
AU2013362755B2 (en) 2012-12-21 2018-09-13 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
RU2530651C1 (ru) * 2013-11-06 2014-10-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии
KR101538264B1 (ko) * 2014-01-24 2015-07-20 계명대학교 산학협력단 티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
CN105255887B (zh) * 2015-07-17 2018-05-18 四川大学 一种重组慢病毒及其在制备治疗可卡因成瘾的药物中的用途
WO2020082037A1 (en) * 2018-10-19 2020-04-23 Auransa Inc. Methods for treating a subtype of small cell lung cancer
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
KR102562739B1 (ko) * 2020-09-11 2023-08-03 연세대학교 산학협력단 암의 기원 세포의 사멸용 약학적 조성물
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
GB1288376A (zh) 1968-10-29 1972-09-06
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) * 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5602172A (en) * 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
WO1998000018A1 (en) * 1996-07-03 1998-01-08 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea
US6008247A (en) * 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6172104B1 (en) * 1998-08-20 2001-01-09 The University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
EP1143959B1 (en) * 1998-09-17 2006-11-02 University Of North Carolina At Chapel Hill Antifungal activity of dicationic molecules
JP3679943B2 (ja) * 1999-03-02 2005-08-03 大日本印刷株式会社 パターン形成体の製造方法
EP1231910B1 (en) 1999-11-16 2009-05-20 Oncozyme Pharma Inc. Pentamidine for treating cancer
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
AU2001258784A1 (en) * 2000-05-22 2001-12-03 Takeda Chemical Industries Ltd. Tyrosine phosphatase inhibitors
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) * 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) * 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
BR0312597A (pt) * 2002-07-11 2005-05-10 Combinatorx Inc Combinações de drogas para o tratamento de neoplasmas
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
JP2007505914A (ja) * 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases

Also Published As

Publication number Publication date
EE200300212A (et) 2003-08-15
NZ525773A (en) 2005-04-29
US6846816B2 (en) 2005-01-25
AU2002246636B2 (en) 2005-12-01
DE60117615T2 (de) 2006-11-09
AU2002246636B8 (en) 2006-01-19
US20050192274A1 (en) 2005-09-01
NO20032036D0 (no) 2003-05-06
PL362690A1 (en) 2004-11-02
TWI259077B (en) 2006-08-01
KR100720205B1 (ko) 2007-05-21
BR0115166A (pt) 2003-12-30
CA2436799A1 (en) 2002-08-01
IS6806A (is) 2003-05-05
AR035500A1 (es) 2004-06-02
DE60117615D1 (de) 2006-04-27
US20030166642A1 (en) 2003-09-04
HRP20030460A2 (en) 2005-04-30
CY1105501T1 (el) 2010-04-28
ES2258566T3 (es) 2006-09-01
ATE318590T1 (de) 2006-03-15
US20070099906A1 (en) 2007-05-03
NO20032036L (no) 2003-07-04
MXPA03003960A (es) 2004-09-10
PT1339399E (pt) 2006-07-31
IL155795A0 (en) 2003-12-23
EP1339399B1 (en) 2006-03-01
RU2286769C2 (ru) 2006-11-10
WO2002058684A2 (en) 2002-08-01
IS2457B (is) 2008-11-15
WO2002058684A3 (en) 2003-04-17
HUP0400529A3 (en) 2006-02-28
EP1339399A2 (en) 2003-09-03
DK1339399T3 (da) 2006-06-19
US6569853B1 (en) 2003-05-27
US7148216B2 (en) 2006-12-12
CN1484525A (zh) 2004-03-24
KR20030048460A (ko) 2003-06-19
HUP0400529A2 (hu) 2004-06-28
JP2004517915A (ja) 2004-06-17
SK5452003A3 (en) 2004-07-07
CA2436799C (en) 2007-12-18

Similar Documents

Publication Publication Date Title
BG107831A (bg) Комбинация от лекарства, по-специално хлорпромазин и пентамидин, за лечение на неопластични заболявания
US6693125B2 (en) Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
AU2002246636A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
US20040029860A1 (en) Anti-proliferative drugs
AU2002218467A1 (en) Anti-proliferative drugs
AU2927999A (en) Use of epothilones for the treatment of cancer
JP2016519684A (ja) 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
JP2005536509A (ja) 新生物の治療のための薬物の組み合わせ
US9867807B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
TW202038932A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
EP2207548B1 (en) Breast cancer therapy
JP2008528640A (ja) バイカレインとバイカリンとの抗腫瘍相乗医薬組成物
CN112439067B (zh) Sglt2抑制剂在制备改善抗肿瘤药物敏感性的产品中的应用
AU2006200697A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
CA2599884A1 (en) Combinations of drugs for the treatment of neoplastic disorders
PT99091B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da triazina e da pirimidina, como ingredientes activos, destinadas a reverter a resistencia aos agentes anticancerosos e antimalaricos
CZ20031240A3 (cs) Kombinace léků (např. chlorpromazinu a pentamidinu) pro léčbu nádorových onemocnění, způsob jejich léčby, farmaceutické prostředky jejich léčby a farmaceutické balení